Now showing items 1-2 of 2
Osteoprotegerin and breast cancer risk by hormone receptor subtype: A nested case-control study in the EPIC cohort
(Journal article; Tidsskriftartikkel; Peer reviewed, 2017-02-08)
Background:<br>Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study.<br>Methods:<br>A case-control ...
Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: Results from the EPIC cohort.
(Journal article; Tidsskriftartikkel; Peer reviewed, 2017-08-31)
Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has ...